The gene signature of this group highly resembled that of the adult GBM-defined “Proneural” group, and the median survival of patients within this group was approximately 18 months (Mackay et al., 2017), while the methylation-based classifications of these two groups resembled others such as the PDGFRA versus EGFR versus MYCN (Korshunov et al., 2017) and the “GBM_pedRTK” versus “GBM_MYCN” versus “HGG_MID” (molecularneuropathology.org/mnp). The gene discussed is MYCN; the disease is glioblastoma.